T cells expressing an anti–B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma
Center for Cancer Research · National Institutes of Health · +3 more institutions
Abstract
Therapies with novel mechanisms of action are needed for multiple myeloma (MM). B-cell maturation antigen (BCMA) is expressed in most cases of MM. We conducted the first-in-humans clinical trial of chimeric antigen receptor (CAR) T cells targeting BCMA. T cells expressing the CAR used in this work (CAR-BCMA) specifically recognized BCMA-expressing cells. Twelve patients received CAR-BCMA T cells in this dose-escalation trial. Among the 6 patients treated on the lowest 2 dose levels, limited antimyeloma activity and mild toxicity occurred. On the third dose level, 1 patient obtained a very good partial remission. Two patients were treated on the fourth dose level of 9 × 10(6) CAR(+) T cells/kg body weight.…
Citation impact
- FWCI
- 45.12
- Percentile
- 100%
- References
- 47
Authors
14- SASyed Abbas AliCorresponding
Center for Cancer Research
- VSVictoria Shi
National Institutes of Health, National Cancer Institute
- IMIrina Marić
National Institutes of Health Clinical Center
- MWMichael Wang
The University of Texas MD Anderson Cancer Center
- DFDavid F. Stroncek
National Institutes of Health Clinical Center
Topics & keywords
- Chimeric antigen receptor
- Antigen
- Multiple myeloma
- Immunology
- Cancer research
- Medicine
- Biology
- T cell